[1] D′Amico G, Bataller R. Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis. J Hepatol, 2018,69:1219-1220.
[2] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014,60:2099-2108.
[3] Tiniakos DG, MauríCIo J, Reeves HL. Fatty liver disease and hepatocellular carcinoma: the pathologist′s view. Adv Exp Med Biol, 2018,1032:55-69.
[4] West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther, 2017,45:983-990.
[5] Li JF, Zheng EQ, Xie M. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies. Gene, 2019,685:143-148.
[6] Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol, 2018,69:1274-1283.
[7] Wang HW, Lai HC, Hu TH, et al. Stratification of hepa-tocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol, 2019,34:442-449. |
